NeurologyLive® Friday 5 — August 22, 2025

Author(s):

Key Takeaways

The July 2025 FDA update includes approvals, label updates, and a complete response letter, summarizing key regulatory actions in neurology.
AAIC 2025 provides groundbreaking insights into Alzheimer’s treatments and diagnostics through expert interviews and key takeaways.
Eric Siemers, MD, emphasizes the benefits of the p-tau 217 biomarker in improving Alzheimer’s disease screening accuracy and reducing patient burden.
Howard Fillit, MD, recaps notable developments in Alzheimer’s prevention, biomarkers, and therapeutics presented at AAIC 2025.
Sam Gandy, MD, PhD, discusses targeting amyloid-β oligomers with Valiltramiprosate, highlighting its potential role in Alzheimer’s disease therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 22, 2025.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Key Considerations in the Use of On-Demand Therapy for Parkinson OFF Episodes: Cheryl Kyinn, PA-C

The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]

2:The Growing Care Impact of Speech and Physical Therapy in Parkinson Disease: Cynthia Fox, PhD, CCC-SLP

The CEO and co-founder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]

3: The Complement Connection in Guillain-Barre and Chronic Inflammatory Demyelinating Polyneuropathy

Explore the role of the complement system in autoimmune neuropathies like GBS and CIDP, and discover innovative therapeutic strategies targeting complement pathways.

4: NeuroVoices: Dennis Rivet, MD, on Expanding the Role of GLP-1 RAs to Idiopathic Intracranial Hypertension and Beyond

The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonweath University discussed the rationale, results, and future directions of GLP-1 RA therapy as a novel treatment strategy for idiopathic intracranial hypertension.

5: Overviewing the Role of Amyloid-ß Oligomers and Valiltramiprosate in Alzheimer Disease: John Hey, PhD

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Subscribe Now!